| Dr Troy L Randle, DO | |
|
1 Brace Rd Ste C, Cherry Hill, NJ 08034-2600 | |
| (856) 428-4100 | |
| (856) 428-5748 |
| Full Name | Dr Troy L Randle |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 21 Years |
| Location | 1 Brace Rd Ste C, Cherry Hill, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710187513 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virtua Our Lady Of Lourdes Hospital | Camden, NJ | Hospital |
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M. Domchek, MD, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, at the American Society of Clinical Oncology Annual Meeting.
For the 25 percent of type-2 diabetes patients who suffer from numbness and extreme nerve pain in their feet, a new dermatological treatment being tested by Northwestern Medicine scientists could potentially help prevent and maybe even reverse the neuropathy.
In a policy paper released today the American College of Physicians reaffirmed its support for increased health care transparency. Healthcare Transparency-Focus on Price and Clinical Performance Information, the first paper in a series of policy papers about transparency, is an introduction and overview of the issues and challenges faced with increased health care transparency.
Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).
› Verified 8 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M. Domchek, MD, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, at the American Society of Clinical Oncology Annual Meeting.
For the 25 percent of type-2 diabetes patients who suffer from numbness and extreme nerve pain in their feet, a new dermatological treatment being tested by Northwestern Medicine scientists could potentially help prevent and maybe even reverse the neuropathy.
In a policy paper released today the American College of Physicians reaffirmed its support for increased health care transparency. Healthcare Transparency-Focus on Price and Clinical Performance Information, the first paper in a series of policy papers about transparency, is an introduction and overview of the issues and challenges faced with increased health care transparency.
Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).
› Verified 8 days ago
| Entity Name | Lourdes Cardiology Services, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912202557 PECOS PAC ID: 5799961751 Enrollment ID: O20110510000163 |
News Archive
The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M. Domchek, MD, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, at the American Society of Clinical Oncology Annual Meeting.
For the 25 percent of type-2 diabetes patients who suffer from numbness and extreme nerve pain in their feet, a new dermatological treatment being tested by Northwestern Medicine scientists could potentially help prevent and maybe even reverse the neuropathy.
In a policy paper released today the American College of Physicians reaffirmed its support for increased health care transparency. Healthcare Transparency-Focus on Price and Clinical Performance Information, the first paper in a series of policy papers about transparency, is an introduction and overview of the issues and challenges faced with increased health care transparency.
Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Troy L Randle, DO 301 Lippincott Dr Ste 410, Marlton, NJ 08053-4197 Ph: (856) 355-0340 | Dr Troy L Randle, DO 1 Brace Rd Ste C, Cherry Hill, NJ 08034-2600 Ph: (856) 428-4100 |
News Archive
The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M. Domchek, MD, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, at the American Society of Clinical Oncology Annual Meeting.
For the 25 percent of type-2 diabetes patients who suffer from numbness and extreme nerve pain in their feet, a new dermatological treatment being tested by Northwestern Medicine scientists could potentially help prevent and maybe even reverse the neuropathy.
In a policy paper released today the American College of Physicians reaffirmed its support for increased health care transparency. Healthcare Transparency-Focus on Price and Clinical Performance Information, the first paper in a series of policy papers about transparency, is an introduction and overview of the issues and challenges faced with increased health care transparency.
Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).
› Verified 8 days ago